Ruben Garcia Biography and Net Worth

General Counsel of FibroBiologics

Ruben A. Garcia joined FibroBiologics as General Counsel in March 2024. He is a member of FibroBiologics’ executive leadership team and leads the company’s legal function.

He most recently served as Senior Vice President, General Counsel and Corporate Secretary at AcelRx Pharmaceuticals, Inc. (n/k/a Talphera, Inc.), where he managed legal and compliance matters, including corporate governance, public company reporting, intellectual property, healthcare compliance, employee relations, litigation, and strategic, finance and commercial transactions. Prior to that, he was Senior Corporate Counsel and Assistant Secretary at Ultragenyx Pharmaceutical Inc., with responsibility for SEC and governance matters. He began his legal career as an attorney with Vinson & Elkins LLP and Jones Day, where he practiced in the areas of capital markets, securities offerings, corporate governance and mergers and acquisitions.

He holds a B.A. in Government and Economics from Georgetown University and a J.D. from Stanford Law School.

What is Ruben A. Garcia's net worth?: The estimated net worth of Ruben A. Garcia is at least $10.26 thousand as of February 27th, 2026. Mr. Garcia owns 9,000 shares of FibroBiologics stock worth more than $10,260 as of October 8th. This net worth approximation does not reflect any other investments that Mr. Garcia may own. Learn More about Ruben A. Garcia's net worth.
How do I contact Ruben A. Garcia?: The corporate mailing address for Mr. Garcia and other FibroBiologics executives is 9350 Kirby Drive, Suite 300, Houston, TX, 77054. FibroBiologics can also be reached via phone at 281-671-5150 and via email at [email protected]. Learn More on Ruben A. Garcia's contact information.
Has Ruben A. Garcia been buying or selling shares of FibroBiologics?: Ruben A. Garcia has not been actively trading shares of FibroBiologics during the past quarter. Most recently, on Friday, February 27th, Ruben A. Garcia bought 2,000 shares of FibroBiologics stock. The stock was acquired at an average cost of $6.60 per share, with a total value of $13,200.00. Following the completion of the transaction, the general counsel now directly owns 9,000 shares of the company's stock, valued at $59,400. Learn More on Ruben A. Garcia's trading history.
Who are FibroBiologics' active insiders?: FibroBiologics' insider roster includes Jason Davis (CFO), Ruben Garcia (General Counsel), Hamid Khoja (Insider), and Pete O'Heeron (Chairman/Founder/CEO). Learn More on FibroBiologics' active insiders.
Are insiders buying or selling shares of FibroBiologics?: During the last year, FibroBiologics insiders bought shares 7 times. They purchased a total of 16,574 shares worth more than $120,485.80. The most recent insider tranaction occured on March, 4th when CEO Pete O'Heeron bought 793 shares worth more than $6,026.80. Insiders at FibroBiologics own 7.3% of the company. Learn More about insider trades at FibroBiologics.
Information on this page was last updated on 3/4/2026.

Ruben A. Garcia Insider Trading History at FibroBiologics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/27/2026	Buy	2,000	$6.60	$13,200.00	9,000
12/11/2025	Buy	7,000	$6.80	$47,600.00	7,000

Ruben A. Garcia Buying and Selling Activity at FibroBiologics

FibroBiologics Company Overview

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

Today's Range

Now: $1.14

$1.07

$1.20

50 Day Range

MA: $1.33

$0.70

$2.11

2 Week Range

Now: $1.14

$0.62

$10.33

Volume

233,803 shs

Average Volume

139,435 shs

Market Capitalization

$7.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.72